In another pre-clinical study, anti-CTLA-4 was administered in mammary tumor mouse models either 7 days before, 1 day after, or 5 days after RT and the best tumor control was achieved when anti-CTLA-4 was given prior to RT. This evidence concerns the gene CTLA4 and breast cancer.